SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (338)11/13/2006 12:49:17 PM
From: Jim Oravetz  Read Replies (1) of 370
 
Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
November 13, 2006 8:00 a.m.


NEW HAVEN, Conn., Nov. 13 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that it had accrued 210 patients to the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M). The trial is evaluating Cloretazine(R)(VNP40101M) in combination with cytarabine for the treatment of relapsed acute myelogenous leukemia (AML).


The protocol for this international Phase III randomized study includes a planned interim analysis on the first 210 patients. With the time required for treating and following these patients for a response assessment, the Company believes that these data should be available for review by the Data Safety Monitoring Board for the trial in March or April of 2007.


The trial is designed to accrue 420 patients if it continues to full accrual. The Company believes that full accrual to the trial can be completed by late 2007 or early 2008.


Ann Cahill, Vice President, Clinical Development of Vion said, "We are proud to have reached the halfway point of accrual to our Phase III trial of Cloretazine(R)(VNP40101M). Together with our pivotal Phase II trial of Cloretazine(R)(VNP40101M) as a single agent in elderly patients with de novo poor-risk AML, our Phase III trial represents an important evaluation of Cloretazine(R)(VNP40101M)'s role in the treatment of AML, a life-threatening disease for many people."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News